Medical device and MedTech insights, news, tips and more

Exactech Announces FDA Breakthrough Device Designation for JointMedica’s Polymotion® Hip Resurfacing System

May 17, 2022


Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Device Designation for JointMedica’s Polymotion® Hip Resurfacing System.

Exactech, a minority shareholder of JointMedica Limited, is collaborating with the United Kingdom-based orthopaedic device designer and manufacturer to deliver the next generation of hip resurfacing to the global market, and holds exclusive global distribution rights to the product.

“This designation by the FDA is a validation of our core belief at JointMedica—that our hip resurfacing device addresses an acute unmet need of relatively younger, active hip arthritis patients,” said Terence Smith, Managing Director of JointMedica.

According to Exactech Chief Strategy Officer, Sharat Kusuma, MD, “We are thrilled that PolyMotion and JointMedica have been recognized as one of only 71 orthopaedic devices that have received breakthrough designation since the inception of this program. We aspire to accelerate Polymotion hip resurfacing development and help more patients get back to all the activities they love.”

The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

“Hip Resurfacing remains an excellent choice for young, active patients, who will inevitably place a higher demand on their hip reconstruction. The introduction of metal-on-vitamin E crosslinked polyethylene hip resurfacing would be most welcomed by me as a practicing surgeon and well-received by my patient community,” said Craig J. Della Valle, MD, of Midwest Orthopaedics at Rush in Chicago, Illinois.

Dr. Della Valle is joined by colleague Scott Marwin, MD, of NYU Langone Orthopedic Hospital, in an advisory role in submitting for the breakthrough designation.

“Through this deep collaboration Exactech and JointMedica are well positioned to bring the Polymotion Hip Resurfacing System to the global market. Partnering with surgeons at the early stages of development has always served a fundamental role in our success,” said Jeff Binder, CEO and Chairman of the Board of Exactech. “Polymotion will complement Exactech’s Alteon® hip arthroplasty portfolio, comprised of substantial advancements in design and materials to time-tested solutions.”

With more than three decades of experience using hard-on-hard articulations in hip resurfacing, Derek McMinn MD, FRCS, and Ronan Treacy, MD, FRCS, designed the Polymotion Hip Resurfacing System to leverage the clinically successful design principles of their previous hip resurfacing devices, now with advanced polyethylene and titanium manufacturing technology. The Polymotion hip offers the biomechanical benefits of hip resurfacing but eliminates metal-on-metal articulating surfaces.

About JointMedica

JointMedica is an orthopaedic design and development “Think Tank,” intending to advance and disseminate new concepts which result in the creation of innovative orthopaedic implants. Our objective is to form close relationships with key orthopaedic surgeons, empowering the creation of products that are highly innovative while at the same time meeting the heightened expectations of patients along with the stringent quality and safety standards that apply to modern orthopaedic implants.


About Exactech

Exactech is a global medical device company that develops and markets orthopaedic implant devices, related surgical instruments and the Active Intelligence® platform of smart technologies to hospitals and physicians. Headquartered in Gainesville, Fla., Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Visit for more information and connect with us on LinkedInVumediYouTubeInstagram and Twitter.

See Full Press Release at the Source: Exactech Announces FDA Breakthrough Device Designation for JointMedica’s Polymotion® Hip Resurfacing Systemevice Designation

Press Release by: Exactech

Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.